Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $28.00 → $38.25 | Buy → Neutral | Chardan Capital |
| 11/19/2021 | $30.00 → $38.25 | Outperform → Sector Perform | RBC Capital |
| 11/18/2021 | $32.00 → $38.25 | Buy → Neutral | HC Wainwright & Co. |
| 8/11/2021 | $36.00 → $25.00 | Buy → Neutral | Goldman Sachs |
| 8/10/2021 | $34.00 → $28.00 | Buy | Chardan Capital |
| 8/10/2021 | $38.00 → $32.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $32.00 | Buy → Neutral | Citigroup |
| 8/6/2021 | $35.00 → $30.00 | Outperform | RBC Capital |
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,
– Reported Positive Top-Line Data From Pivotal PHYOX™2 Clinical Trial of Nedosiran Investigational GalXC™ RNAi Therapy for Treatment of Primary Hyperoxaluria (PH) – – Initiated Phase 1 Clinical Trial of DCR-AUD for the Treatment of Alcohol Use Disorder (AUD) – – Company Plans to Unveil First GalXC-Plus™ Extrahepatic Target in Early 2022 – – Cash Runway Extends Into 2025 – – Company to Host Conference Call Today at 8:30 a.m. ET – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported its financial results for the third quarter ended September 30, 2021 and provided a business update. "We had a
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide a general business update. The conference call will be webcast live and will be available from the "Investors & Media" section of the Dicerna website, www.dicerna.com. The webcast will also be archived on the Company's website. The conference call can be accessed by dialing (855) 4
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. ((Dicerna, NASDAQ:DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk's cash tender offer for Dicerna, Novo Nordisk has today acquired all outstanding shares of common stock of Dicerna at a price of USD 38.25 per share in cash, without interest and less any applicable tax withholding. Novo Nordisk has been advised by the depositary for the tender offer that a total of approximately 64,946,526 shares of Dicerna's common stock were validly tendered and not validly withdrawn in the tender offer as of the tender offer expiration at 5.00 pm EST on 27 December 2021,
Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Novo Nordisk's cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021. As previously announced on November 18, 2021, Novo Nordisk commenced a cash tender offer to purchase all outstanding shares of Dicerna common stock for $38.25 per share in cash, without interest and subject to any withholding of taxes. The expiration of the HSR waiting period satisfies one of the conditions necessary for the consummation of the tender offer. Other conditions remain to be satisfied, inclu
SVB Leerink boosted the price target on Edwards Lifesciences Corporation (NYSE:EW) from $130 to $135. Edwards Lifesciences shares rose 1% to trade at $120.68 on Thursday. Keybanc raised The Sherwin-Williams Company (NYSE:SHW) price target from $350 to $384. Sherwin-Williams shares rose 1% to $345.68 on Thursday. Piper Sandler cut Udemy, Inc. (NASDAQ:UDMY) price target from $37 to $34. Udemy shares fell 2% to trade at $20.65 on Thursday. Needham lowered the price target on Esperion Therapeutics, Inc. (NASDAQ:ESPR) from $20 to $12. Esperion Therapeutics shares dropped 9% to $5.34 on Thursday. JP Morgan lifted Phillips 66 (NYSE:PSX) price target from $83 to $93. Phillips 66 shar
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ:NVEI) was changed from Market Perform to Outperform. BMO Capital upgraded the previous rating for Nuvei Corp (NASDAQ:NVEI) from Market Perform to Outperform. For Cadence Bank (NYSE:CADE), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. Cadence Bank earned $0.67 in the third quarter, compared to $0.40 in the year-ago quarter. At the moment, the stock has a 52-week-high of $32.12 and a 52-week-low of $14.47. Cadence Bank closed at $29.39 at the end of the last trading period. According to Raymond James, the prior rating for Boyd Gaming Corp (NYSE:BYD) was changed from Outperform to Strong
Chardan Capital analyst Keay Nakae downgrades Dicerna Pharmaceuticals (NASDAQ:DRNA) from Buy to Neutral and raises the price target from $28 to $38.25.
Chardan Capital downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $28.00 previously
RBC Capital downgraded Dicerna Pharmaceuticals from Outperform to Sector Perform and set a new price target of $38.25 from $30.00 previously
HC Wainwright & Co. downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $38.25 from $32.00 previously
SC 13G - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
SC 13G/A - Dicerna Pharmaceuticals Inc (0001399529) (Subject)
15-12B - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
EFFECT - Dicerna Pharmaceuticals Inc (0001399529) (Filer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
4 - Dicerna Pharmaceuticals Inc (0001399529) (Issuer)
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
– Rob Ciappenelli Appointed Chief Strategy Officer and Marc Abrams, Ph.D., Promoted to Senior Vice President of Discovery Research – – Kristen Sheppard, Esq., Joins Company as Senior Vice President of Investor Relations and Corporate Communications – Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced the appointment of Rob Ciappenelli as Chief Strategy Officer, the promotion of Marc Abrams, Ph.D., to Senior Vice President, Discovery Research and the addition of Kristen Sheppard, Esq., to Dicerna's executive leadership team as Senior Vice President, Investor Rela
LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 23,350 shares of common stock and 5,675 restricted stock units (“RSUs”) to be distributed among three new employees with a grant date of Jan. 4, 2021 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $22.07